Individualized Information Sharing Important in All Stages of Cancer Care
the Cancer Therapy Advisor take:
Appropriate, individualized sharing of information for patients with cancer was determined to be important during treatment, at the time of hospital discharge, and in primary care, according to an article published online in the journal European Journal of Cancer Care.
The authors of this study aimed to explore cancer survivors’ experiences regarding information they were given about potential long-term and late effects of pelvic radiotherapy.
Twenty-eight cancer survivors who had received pelvic radiotherapy for a range of cancers (1-11 years prior to the study) were interviewed. Participants from a larger questionnaire survey of patients treated at another hospital were also interviewed.
Results showed the patients acknowledged the potential ability of information to reassure and inform patients, but also identified its ability to produce undesirable effects or raise anxieties about future problems.
Furthermore, the participants identified the importance of the timing, amount of information provided, and context of their situations—value was also placed on information based on personal experience.
Appropriate, individualized sharing of information for patients with cancer was determined to be important during all stages.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Ginkgo Biloba and Cancer
- Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC